COMBINATION THERAPY

• US 20130302274A1
• Filed: 11/21/2012
• Published: 11/14/2013
• Est. Priority Date: 11/25/2011
• Status: Abandoned Application

• Current Assignee: Roche Glycart AG (Roche Holding AG)
• Original Assignee: Roche Glycart AG (Roche Holding AG)
• Inventors: KLEIN, CHRISTIAN, LAPREVOTTE, EMILIE, QUILLET-MARY, ANNE
• Application Number:
  US13/683,519
• Publication Number:
  US 20130302274A1
• Time in Patent Office: Days
• US Class Current: 424/85.2
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/2033 IL-5
• CPC Class Codes: A61K 38/2086 IL-13 to IL-16
• CPC Class Codes: A61K 39/39558 against tumor tissues, cells, antigens
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61N 2005/1098 Enhancing the effect of the particle by an injected agent or implanted device
• CPC Class Codes: A61N 5/10 X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy A61N5/01 takes precedence
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/2887 against CD20
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/41 Glycosylation, sialylation, or fucosylation
• CPC Class Codes: C07K 2317/54 F(ab')2
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]

Abstract

The present invention is directed to the combination therapy of an afucosylated antibody specifically binding to a tumor-antigen with human IL-15 for the treatment of cancer.

Claims

1. Anti-CD20 antibody in combination with human IL-15 for use in treatment of cancer.

2. Anti-CD20 antibody according to claim 1 characterized in that said CD20 antibody is an afucosylated antibody with an amount of fucose of 60% or less, and said cancer is a CD20 expressing cancer.

3. Anti-CD20 antibody according to any one of claim 2, characterized in that said anti-CD20 antibody is a humanized B-Ly1 antibody.

4. Anti-CD20 antibody according to any one of claims 1 to 3, characterized in that said anti-CD20 antibody is obinutuzumab.

5. Anti-CD20 antibody according to any one of claims 1 to 4, characterized in that said the cancer is leukemia.

6. Anti-CD20 antibody according to any one of claims 1 to 5, characterized in that said the cancer is chronic lymphocytic leukemia.

7. Anti-CD20 antibody according to any one of claims 1 to 6, characterized in that the Anti-CD20 antibody is an afucosylated antibody which shows an increased ADCC.

8. Anti-CD20 antibody according to any one of claims 1 to 7, characterized in that one or more additional other cytotoxic, chemotherapeutic or anti-cancer agents, or compounds or ionizing radiation that enhance the effects of such agents are administered.

9. A method for the treatment of cancer, comprising administering to a patient in need of such treatment an anti-CD20 antibody and a human IL-15.

10. The method of claim 9, comprising co-administering the anti-CD20 antibody and the human IL-15.

11. The method of claim 9 or 10, wherein the anti-CD20 antibody and the human IL-15 are administered sequentially or simultaneously.

12. The method according to claim 9, wherein the CD20 antibody is an afucosylated antibody with an amount of fucose of 60% or less, and said cancer is a CD20 expressing cancer.

13. The method according to claim 9, wherein the anti-CD20 antibody is a humanized B-Ly1 antibody.

14. The method according to claim 9, wherein the anti-CD20 antibody is obinutuzumab.

15. The method according to claim 9, wherein the cancer is leukemia.

16. The method according to claim 15, wherein the leukemia is chronic lymphocytic leukemia.

17. The method according to claim 9, wherein the anti-CD20 antibody is an afucosylated antibody which shows an increased ADCC.

18. The method according to claim 9, wherein one or more additional other cytotoxic agent, chemotherapeutic agent, anti-cancer agent, ionizing radiation, compound, or agents that enhance the effects of such agents are administered.

19. A composition comprising an anti-CD20 antibody and a human IL-15.

20. The composition according to claim 19, further comprising a cytotoxic agent, chemotherapeutic agent or an anti-cancer agent.